29th Jun 2005 07:01
Sinclair Pharma PLC29 June 2005 SINCLAIR PHARMA PLC Analyst R&D meeting London, UK, 29 June 2005: Sinclair Pharma plc ("Sinclair" or the "Company")(SPH.L), the specialty pharmaceutical company, announces that it is todayholding an R&D briefing in London for investors and analysts. The briefing willfocus on the Company's team, processes, products and R&D strategy. The Companyalso announces today current trading and, in separate announcement, additionalproduct newsflow. The key speakers at the R&D presentation include: • Dr. Michael Flynn, Sinclair Chief Executive will give an introduction and overview and introduce Sinclair Executives. • Dr William Abramovits, principal investigator of a recent AtopiclairTM multi-center study performed on the Sinclair product in the US will make a presentation on the positive results. • Prof Rolf Attstrom, a distinguished periodontal disease specialist, based at the renowned University of Lund in Sweden will make a presentation about periodontal disease and the use of Decapinol(R). • Company Executives will present on current developments and pipeline. • Jerry Randall, ACA, Chief Financial Officer, will summarise the meeting. The agenda for the R&D session is summarized below: New Skin Products SPHD 400 - A new topical product concept for the treatment of psoriasis. AtopiclairTM Fluid - A fluid formulation of AtopiclairTM. Application overlarge areas of the body is made easier for patients with atopic dermatitis orcontact dermatitis. Dermachronic - A non allergenic general use moisturiser and cleanser forpatients with sensitive skin. New products for oral care Aloclair(R) patch - A soluble patch for application to single large ulcers totreat pain and protect the ulcer from trauma and irritation. AlogonTM Spray - An easy to use treatment for sore throat. Decapinol(R) toothpaste - A toothpaste (incorporating Decapinol) used for thetreatment of gingivitis. Decapinol(R) Gel - A 'professional use only' product for the intensive treatmentof gum infections. SPH0200 - A product combining Decapinol with polymer technology to create alonger acting once daily treatment for gingivitis. New Products for Eye diseases SPHP 700 - A new product concept for the treatment of dry eye syndrome. SPH 720 - A non steroid product for the treatment of inflammatory conditions ofthe eye such as seasonal allergic conjunctivitis. Sinclair will also touch on early stage projects including SPHD 420 for thetreatment of acne and SPHR 900 for herpes simplex. Trading update Sinclair expects to finish the year to June 2005 with total revenues ahead ofmarket expectations and significantly above the reported revenue for theprevious year. This is mainly due to the inclusion of the AtopiclairTM licensefees from US licensee Chester Valley Pharmaceuticals. As a consequence of thestronger sales, operating losses are expected to be better than anticipatedalthough the full benefit of this is reduced by a change of business mix. Commenting Chief Executive, Dr Michael Flynn said: "We aim to develop products which are needed to satisfy unmet patient needs andwhich offer clear differentiating features and benefits over the competition.Most of our products come from patented technology platforms and fromcombinations of more than one patented technology. Up to now we have informedthe market about products when we are actually in the registration process, buthaving had good regulatory success to date with products which have passed proofof concept we are now unveiling a major part of our pipeline. We believe that wewill be able to establish strong claims and have protected products which havethe potential to compete with market leaders. We now have a portfolio ofproducts which we believe can competitively address a large part of the US$8billion skin diseases market and most painful conditions of the mouth andthroat. We are now extending the use of our platform technologies to othertherapeutic areas such as selected eye diseases and have been exploring newapplications of our technologies in other therapeutic areas." For further information on the R&D briefing, taking place at 3pm today, please contact Mo Noonan at Financial Dynamics on 020 7831 3113. Enquiries: Contact details Sinclair Pharma plcDr Michael Flynn, CEO Tel: +44 (0) 1483 426 644Jerry Randall ACA, CFO John Barrington-Carver, Corp. PR Tel: Mobile +44 (0) 7831 655 630 Financial DynamicsLucy Briggs Tel +44 (0) 207 831 3113 Sinclair Pharma plc Sinclair Pharma plc based in Godalming in the UK, is quoted on the AlternativeInvestment Market (AIM) on the London Stock Exchange and has focused on theacquisition and development of niche patented pharmaceutical products in thefields of oral health, oncology support and dermatology, and bringing them tothe international market place via out-licensing partners. The Company combinesproduct evaluation, product development, regulatory and business developmentexpertise to add value to its acquired and in-house developed products. A keyelement of the Sinclair business model is to minimise risk and exposure byavoiding involvement in lengthy R&D programmes and rapidly achieving globaldistribution through a network of marketing partners. The Company has alreadylicensed its products for distribution in over 40 countries around the world. www.sinclairpharma.com "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Some or all of the statements in this document that relate to futureplans, expectations, events, performances and the like are forward-lookingstatements, as defined in the US Private Securities Litigation Reform Act of1995. Actual results of events could differ materially from those described inthe forward- looking statements due to a variety of factors. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma